In response to:

Don't Let Obama Kill "Pills for Profit"

Moonbat Exterminator Wrote: Jan 29, 2013 1:06 PM
From Bastiat, we have the seen and the unseen. Restricting the seen by reducing the ability of a pharma company to earn a positive rate of return on R&D by necessity restricts those expenses. It may sound superficially unfair to the customers who pay higher prices, but those prices, which are the seen, include seed money for future products, which are unseen. From Business 101 for Children and Libs, if you want to remain in business, you must be able to sell your product for at least as much as it cost you to bring it to market.

Biotech company Excelixis CEO George Scangos likes to quote oil wildcatter JP Getty when asked about his philosophy for success: “Get up early; work hard; find oil,” he deadpans.

And under the direction of dry-humored Scangos, the San Francisco-based company is drilling a lot of research holes, so to speak.

They have to: Success in the biotech industry is measured incrementally, not in big steps. It’s a cash-and-time intensive industry where success is painstaking, rare and, because of Obamacare and other regulatory burdens from the administration, likely to become even rarer.   

According to Plunkett Research, Ltd in 2010 it...

Related Tags: Obama